Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

The list of currently pending claims is presented below.

1. (Currently amended) A method of modulating an Edg-7 receptor
2 mediated biological activity comprising contacting a cell expressing the Edg-7 receptor with an
3 amount of an a modulator of the Edg-7 receptor sufficient to modulate the Edg-7 receptor
4 mediated biological activity wherein the modulator is a compound of the structural formula
5 Formula (I):

$$R_4$$
 R_7
 X
 R_1
 R_1

6

or a pharmaceutically available acceptable solvate or hydrate thereof, wherein; 7 each of R₁, R₂, R₃, R₄ and R₇ is a member independently selected from the group 8 consisting of -H, -halo, -NO₂, -CN, -C(R_5)₃, -(CH₂)_mOH, -N(R_5)(R_5), -9 $O(CH_2)_mR_5$, $-C(O)R_5$, $-C(O)NR_5R_5$, $-C(O)NH(CH_2)_m(R_5)$, $-OCF_3$, -benzyl, 10 $-CO_2CH(R_5)(R_5)$, $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, 11 -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₅-C₁₀)cycloalkenyl, 12 -(C_5)heteroaryl, -(C_6)heteroaryl, -(C_5 - C_{10})heteroaryl, -naphthyl, 13 $-(C_3-C_{10})$ heterocycle, $-CO_2(CH_2)_mR_5$, -N(OH)aryl, $-NHC(O)R_5$, $-NHC(O)OR_5$, 14 -NHC(O)NHR₅, -heterocylcoalkyl -heterocycloalkyl, -C(S)N(R₅)(R₅), 15 16 $-(C_1-C_{10})$ alkylNHC(O)(CH₂)_mR₅, $-(C_1-C_{10})$ alkylNR₅R₅, $-S(O)_2N(R_5)C(O)NH(heteroaryl)$, $-OC(O)(CH_2)_mCHR_5R_5$, $-CO_2(CH_2)_mCHR_5R_5$, 17 $-OC(O)OR_5$, $-SR_5$, $-S(O)R_5$, $-S(O)_2R_5$, $-S(O)_2NHR_5$, or and 18

$$- \left\langle \begin{array}{c} (R_6)_p \end{array} \right\rangle$$

19 20 wherein each R₅ and R₆ is a member independently selected from the group consisting of -21 H, -halo, -NO₂, -CN, -OH, -CO₂H, -N(C_1 - C_{10})alkyl(C_1 - C_{10})alkyl, 22 $-O(C_1-C_{10})$ alkyl, $-C(O)(C_1-C_{10})$ alkyl, $-C(O)NH(CH_2)_m(C_1-C_{10})$ alkyl, 23 -OCF₃, -benzyl, -CO₂(CH₂)_mCH((C_1 - C_{10})alkyl(C_1 - C_{10})alkyl), 24 $-CO_2(C_1-C_{10})$ alkyl, $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, 25 -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₅-C₁₀)cycloalkenyl, 26 - (C_5) heteroaryl, - (C_6) heteroaryl, -phenyl, naphthyl, - (C_3-C_{10}) heterocycle, 27 $-CO_2(CH_2)_m(C_1-C_{10})$ alkyl, $-CO_2(CH_2)_mH$, $-NHC(O)(C_1-C_{10})$ alkyl, 28 29 $-NHC(O)NH(C_1-C_{10})$ alkyl, -NH(aryl), -N=C(aryl), 30 $-OC(O)O(C_1-C_{10})$ alkyl, or and $-SO_2NH_2$; X is selected from CH₂, C=O, O, S, SO₂, C, or and NR₅; 31 R₁, R₂, R₃ R₄ and R₇ taken in any combination can form one or more substituted or 32 unsubstituted 5 or 6 membered cyclic or heterocyclic rings or a 6-membered 33 aromatic ring; 34 R_1 , R_2 , R_3 , R_4 and R_7 can also be an electron such that when two groups are on adjacent 35 carbon atoms they form a double bond; 36 two R₆ groups on adjacent carbon atoms can together form a 5 or 6 membered cyclic or 37 38 heterocyclic ring or a 6-membered aromatic ring; each m is independently an integer ranging from 0 to 8; and 39 each p is independently an integer ranging from 0 to 5. 40 1 2. (Currently amended) A method of modulating an Edg-7 receptor 2 mediated biological activity in a subject comprising administering to the subject a therapeutically effective amount of a modulator of the Edg-7 receptor wherein the modulator is 3

a compound of the structural formula Formula (II): structural formula (II):

4

5

$$\begin{array}{c|c}
R_4 & R_2 \\
R_7 & X & R_1
\end{array}$$
(II)

or a pharmaceutically available acceptable solvate or hydrate thereof, wherein; 6 each of R₁, R₂, R₃, R₄ and R₇ is a member independently selected from the group 7 8 consisting of -H, -halo, -NO₂, -CN, -C(R_5)₃, -(CH₂)_mOH, -N(R_5)(R_5), - $O(CH_2)_mR_5$, $-C(O)R_5$, $-C(O)NR_5R_5$, $-C(O)NH(CH_2)_m(R_5)$, $-OCF_3$, -benzyl, 9 $-CO_2CH(R_5)(R_5)$, $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, 10 -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₅-C₁₀)cycloalkenyl, 11 - (C_5) heteroaryl, - (C_6) heteroaryl, - (C_5-C_{10}) heteroaryl, -naphthyl, 12 -(C₃-C₁₀)heterocycle, -CO₂(CH₂)_mR₅, -N(OH)aryl, -NHC(O)R₅, -NHC(O)OR₅, 13 14 -NHC(O)NHR₅, -heterocylcoalkyl -heterocycloalkyl, -C(S)N(R₅)(R₅), 15 $-(C_1-C_{10})$ alkylNHC(O)(CH₂)_mR₅, $-(C_1-C_{10})$ alkylNR₅R₅, $-S(O)_2N(R_5)C(O)NH(heteroaryl), -OC(O)(CH_2)_mCHR_5R_5, -CO_2(CH_2)_mCHR_5R_5,\\$ 16 17 $-OC(O)OR_5$, $-SR_5$, $-S(O)R_5$, $-S(O)_2R_5$, $-S(O)_2NHR_5$, or and 18

wherein 19 20 each R₅ and R₆ is a member independently selected from the group consisting of -H, -halo, -NO₂, -CN, -OH, -CO₂H, -N(C_1 - C_{10})alkyl(C_1 - C_{10})alkyl, 21 $-O(C_1-C_{10})$ alkyl, $-C(O)(C_1-C_{10})$ alkyl, $-C(O)NH(CH_2)_m(C_1-C_{10})$ alkyl, 22 -OCF₃, -benzyl, -CO₂(CH₂)_mCH((C_1 - C_{10})alkyl(C_1 - C_{10})alkyl), 23 $-CO_2(C_1-C_{10})$ alkyl, $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, C_1-C_{10} 24 25 C_{10} -(C_2 - C_{10})alkynyl, -(C_3 - C_{10})cycloalkyl, -(C_8 - C_{14})bicycloalkyl, $-(C_5-C_{10})$ cycloalkenyl, $-(C_5)$ heteroaryl, $-(C_6)$ heteroaryl, -phenyl, naphthyl, 26 -(C_3 - C_{10})heterocycle, - $CO_2(CH_2)_m(C_1$ - C_{10})alkyl, - $CO_2(CH_2)_mH$, 27

28			-NHC(O)(C_1 - C_{10})alkyl, -NHC(O)NH(C_1 - C_{10})alkyl, -NH(aryl),
29			-N=C(aryl), -OC(O)O(C_1 - C_{10})alkyl, $\Theta = \underline{\text{and}} -SO_2NH_2$;
30	X is selected from C, or and N;		
31	$R_1, R_2,$	R ₃ , R	4 and R ₇ taken in any combination can form one or more substituted or
32		unsub	ostituted 5 or 6 membered cyclic or heterocyclic rings or a 6-membered
33		aroma	atic ring;
34	R ₁ , R ₂ , R ₃ , R ₄ and R ₇ can also be an electron such that when two groups are on adjacent		
35		carbo	n atoms they form a double bond;
36	two R_6 groups on adjacent carbon atoms can together form a 5 or 6 membered cyclic or		
37 ·		hetero	ocyclic ring or a 6-membered aromatic ring;
8	each m is independently an integer ranging from 0 to 8; and		
89	each p	is inde	ependently an integer ranging from 0 to 5.
1		3.	(Original) The method of Claim 1 or 2, wherein the modulator is an
2	agonist.		
1		4.	(Original) The method of Claim 1 or 2, wherein the modulator is an
2	antagonist.		
1		_	(Out aire 1) The mosth of af Claim 1 and who main the medulator exhibits at
1		5.	(Original) The method of Claim 1 or 2, wherein the modulator exhibits at
2	least about 20	JU fold	l inhibitory selectivity for Edg-7 relative to other Edg receptors.
1		6.	(Original) The method of Claim 1 or 2, wherein the modulator exhibits at
2	least about 40	o fold	inhibitory selectivity for Edg-7 relative to other Edg receptors.
1		7.	(Original) The method of Claim 1 or 2, wherein the modulator exhibits at
2	least about 12	2 fold	inhibitory selectivity for Edg-7 relative to other Edg receptors.
1		8.	(Original) The method of Claim 1 or 2, wherein the modulator exhibits at
2	least about 5 fold inhibitory selectivity for Edg-7 relative to other Edg receptors.		

9. (Original) The method of Claim 1 or 2, wherein the modulator exhibits at 1 least about 20 fold inhibitory selectivity for Edg-7 relative to other Edg receptors. 2 1 10. (Original) The method of Claim 1 or 2, wherein the modulator exhibits at least about 200 fold inhibitory selectivity for Edg-7 relative to Edg-4 and Edg-2 receptors. 2 1 11. (Original) The method of Claim 1 or 2, wherein the modulator exhibits at 2 least about 40 fold inhibitory selectivity for Edg-7 relative to Edg-4 and Edg-2 receptors. 12. (Original) The method of Claim 1 or 2, wherein the modulator exhibits at 1 least about 12 fold inhibitory selectivity for Edg-7 relative to Edg-4 and Edg-2 receptors. 2 (Original) The method of Claim 1 or 2, wherein the modulator exhibits at 1 13. 2 least about 5 fold inhibitory selectivity for Edg-7 relative to Edg-4 and Edg-2 receptors. 14. (Original) The method of Claim 1 or 2, wherein the biological activity is 1 2 cell proliferation. 1 15. (Original) The method of Claim 14, wherein the modulator exhibits at 2 least about 200 fold inhibitory selectivity for Edg-7 relative to other Edg receptors. 16. (Original) The method of Claim 14, wherein the modulator exhibits at 1 2 least about 5 fold inhibitory selectivity for Edg-7 relative to other Edg receptors. (Original) The method of Claim 14, wherein the modulator exhibits at 17. 2 least about 200 fold inhibitory selectivity for Edg-7 relative to Edg-4 and Edg-2 receptors. 18. (Original) The method of Claim 14, wherein the modulator exhibits at 1 2 least about 5 fold inhibitory selectivity for Edg-7 relative to Edg-4 and Edg-2 receptors. 1 19. (Currently amended) The method of Claim 14, wherein cell proliferation 2 leads to cancer selected from the group consisting of ovarian cancer, peritoneal cancer,

3 endometrial cancer, cervical cancer, breast cancer, colon cancer or and prostrate prostate 4 cancer. 20. (Original) The method of Claim 14, wherein cell proliferation is 1 2 stimulated by LPA. (Currently amended) The method of Claim 1 or 2, wherein the biological 1 21. activity is selected from the group consisting of calcium mobilization, VEGF synthesis, IL-8 2 synthesis, platelet activation, cell migration, phosphoinositide hydrolysis, inhibition of cAMP 3 formation, actin polymerization, apoptosis, angiogenesis, inhibition of wound healing, 4 5 inflammation, cancer invasiveness, supressing autoimmune responses, or and atherogenesis. (Currently amended) The method of Claim 1 or 2 wherein the modulator 1 22. 2 binds to the Edg-7 receptor with a binding constant of at least about 10 nm nM. (Currently amended) The method of Claim 1 or 2 wherein the modulator 1 23. binds to the Edg-7 receptor with a binding constant between about 100 fM and 1 μM. and 100 2 3 fM. (Original) The method of Claim 1 or 2, wherein the modulator is a 1 24. 2. nucleic acid, protein or carbohydrate. 1 25. (Original) The method of Claim 1 or 2, wherein the modulator is an organic molecule of molecular weight of less than 750 daltons. 2 26. (Currently amended) The method of Claim 1, wherein the cell is selected 1 from the group consisting of a hepatoma cell, an ovarian cell, an epithelial cell, a fibroblast cell, 2 a neuronal cell, a carcinoma cell, a pheochromocytoma cell, a myoblast cell, a platelet cell or 3 4 and a fibrosarcoma cell. 27. (Currently amended) The method of Claim 21 26, wherein the cell is 1 2 selected from the group consisting of OV202 human ovarian cell, a HTC rat hepatoma cell, a CAOV-3 human ovarian cancer cell, MDA-MB-453 breast cancer cell, MDA-MB-231 breast 3

- 4 cancer cell, HUVEC cells A431 human epitheloid carcinoma cell or and a HT-1080 human
- 5 fibrosarcoma cell.

1

3

4

5

6

2

3

4

5

6

- 28. (Currently amended) The method of Claim 1 or 2 wherein the modulator
- 2 has <u>a the following structural</u> formula <u>selected from</u>:

- 1 **29.** (Currently amended) A r
 - 29. (Currently amended) A method for treating or preventing a disease or condition selected from the group consisting of cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, or and cardiovascular diseases in a patient in need of said treatment or said prevention, said method comprising administering to a said patient in need of such treatment or prevention a therapeutically effective amount of a compound of structural formula Formulae (I) or (II).
- .
 1 (Currently amended) A method for treating or preventing a disease or
- 2 <u>condition selected from the group consisting of ovarian cancer, peritoneal cancer, endometrial</u>

3	cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small		
4	intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer, prostrate prostate		
5	cancer, adult respiratory distress syndrome (ARDS), asthma, transcorneal freezing, cutaneous		
6	burns, ischemia or and artheselerosis atherosclerosis in a patient in need of said treatment or		
7	said prevention, said method comprising administering to a said patient in need of such		
8	treatment or prevention a therapeutically effective amount of a compound of structural formula		
9 -	Formulae (I) or (II).		
_			
1	31. (Currently amended) A method for treating or preventing <u>a disease or</u>		

- condition selected from the group consisting of cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, or and cardiovascular diseases in a patient in need of said treatment or said prevention, said method comprising administering to a said patient in need of such treatment or prevention a therapeutically effective amount of a compound of structural formula Formulae (I) or (II) and one or more agonists or antagonists of an Edg-7 receptor.
- 22. (Currently amended) A method for treating or preventing a disease or condition selected from the group consisting of cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, of and cardiovascular diseases in a patient in need of said treatment or said prevention, said method comprising administering to a said patient in need of such treatment or prevention a therapeutically effective amount of a compound of structural formula Formulae (I) or (II) and one or more drugs useful in treating or preventing cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, or cardiovascular diseases.
 - 33. (New) A method of treating cancer in a patient comprising: administering to the patient a therapeutically effective amount of a modulator of an Edg-7 receptor wherein the modulator is a compound of Formula (III):

$$R_4$$
 R_2
 R_7
 R_1

or a pharmaceutically acceptable solvate or hydrate thereof, wherein 2 3 R_2 , R_3 and R_7 are H; 4 R₄ is an alkoxy group; 5 R_1 is a member selected from the group consisting of -H, -halo, -NO₂, -CN, -C(R_5)₃, 6 $-(CH_2)_mOH$, $-N(R_5)(R_5)$, $-O(CH_2)_mR_5$, $-C(O)R_5$, $-C(O)NR_5R_5$, -7 $C(O)NH(CH_2)_m(R_5)$, $-OCF_3$, -benzyl, $-CO_2CH(R_5)(R_5)$, $-(C_1-C_{10})alkyl$, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$ cycloalkyl, $-(C_8C_{14})$ bicycloalkyl, 8 9 $-(C_5-C_{10})$ cycloalkenyl, $-(C_5)$ heteroaryl, $-(C_6)$ heteroaryl, $-(C_5-C_{10})$ heteroaryl, -naphthyl, $-(C_3-C_{10})$ heterocycle, $-CO_2(CH_2)_mR_5$, -N(OH)aryl, $-NHC(O)R_5$, 10 -NHC(O)OR₅, -NHC(O)NHR₅, -heterocycloalkyl, -C(S)N(R₅)(R₅), 11 $-(C_1-C_{10})$ alkylNHC(O)(CH₂)_mR₅, $-(C_1-C_{10})$ alkylNR₅R₅, 12 13 $-S(O)_2N(R_5)C(O)NH(heteroaryl)$, $-OC(O)(CH_2)_mCHR_5R_5$, $-CO_2(CH_2)_mCHR_5R_5$, 14 $-OC(O)OR_5$, $-SR_5$, $-S(O)R_5$, $-S(O)_2R_5$, $-S(O)_2NHR_5$, and

15

1

16 wherein

each R₅ and R₆ is a member independently selected from -H, -halo, -NO₂, -CN, 17 -OH, $-CO_2H$, $-N(C_1-C_{10})$ alkyl (C_1-C_{10}) alkyl, $-O(C_1-C_{10})$ alkyl, 18 $-C(O)(C_1-C_{10})$ alkyl, $-C(O)NH(CH_2)_m(C_1-C_{10})$ alkyl, $-OCF_3$, -benzyl, 19 $-CO_2(CH_2)_mCH((C_1-C_{10})alkyl(C_1-C_{10})alkyl), -CO_2(C_1-C_{10})alkyl,$ 20 $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $C_1-C_{10}-(C_2-C_{10})$ alkynyl, 21

37.

-(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₅-C₁₀)cycloalkenyl, 22 -(C_5)heteroaryl, -(C_6)heteroaryl, -phenyl, naphthyl, -(C_3 - C_{10})heterocycle, 23 $-CO_2(CH_2)_m(C_1-C_{10})$ alkyl, $-CO_2(CH_2)_mH$, $-NHC(O)(C_1-C_{10})$ alkyl, 24 -NHC(O)NH(C₁-C₁₀)alkyl, -NH(aryl), -N=C(aryl), 25 $-OC(O)O(C_1-C_{10})$ alkyl, and $-SO_2NH_2$; 26 each m is independently an integer ranging from 0 to 8; and 27 each p is independently an integer ranging from 0 to 5. 28 (New) The method of claim 33, wherein said alkoxy group in R₄ is a 1 34. 2 methoxy group. (New) The method of claim 34, wherein said R_1 is a -(C_6)heteroaryl 1 35. 2 group. (New) The method of claim 35, wherein said -(C₆)heteroaryl group is 36. 1 2 substituted.

(New) The method of claim 36, wherein said compound has the formula:

2

1

1 38. (New) The method of claim 33, wherein said cancer is selected from the 2 group consisting of ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, 3 breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid

4 cancer, lung cancer, kidney cancer, pancreas cancer and prostate cancer.